A2RR34 Stock Overview
Develops medicines for the treatment of intractable diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Arrowhead Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.07 |
| 52 Week High | US$23.51 |
| 52 Week Low | US$12.18 |
| Beta | 0.93 |
| 11 Month Change | -2.76% |
| 3 Month Change | -11.34% |
| 1 Year Change | -18.58% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -59.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| A2RR34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | -2.2% | 3.4% | 0.7% |
| 1Y | -18.6% | 11.5% | -0.7% |
Return vs Industry: A2RR34 underperformed the BR Biotechs industry which returned 11.5% over the past year.
Return vs Market: A2RR34 underperformed the BR Market which returned -0.7% over the past year.
Price Volatility
| A2RR34 volatility | |
|---|---|
| A2RR34 Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in BR Market | 8.1% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: A2RR34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine A2RR34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 525 | Chris Anzalone | arrowheadpharma.com |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases.
Arrowhead Pharmaceuticals, Inc. Fundamentals Summary
| A2RR34 fundamental statistics | |
|---|---|
| Market cap | R$15.21b |
| Earnings (TTM) | -R$3.13b |
| Revenue (TTM) | R$114.21m |
133.2x
P/S Ratio-4.9x
P/E RatioIs A2RR34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A2RR34 income statement (TTM) | |
|---|---|
| Revenue | US$19.65m |
| Cost of Revenue | US$0 |
| Gross Profit | US$19.65m |
| Other Expenses | US$558.28m |
| Earnings | -US$538.64m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.33 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,741.43% |
| Debt/Equity Ratio | 99.1% |
How did A2RR34 perform over the long term?
See historical performance and comparison